Depression screening using the Patient Health Questionnaire‐9 administered on a touch screen computer

Fann, Jesse R.; Berry, Donna L.; Wolpin, Seth; Austin-Seymour, Mary; Bush, Nigel; Halpenny, Barbara; Lober, William B.; McCorkle, Ruth

doi:10.1002/pon.1368

Cited by 125 publications

(92 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The Patient Health Questionnaire-9 (PHQ-9), one of the screening tools chosen, showed a higher PPV in this sample when compared with previous studies. [29][30][31] One possible explanation for this finding could be the high prevalence of mood disorders in this Chilean population (almost 40%), seen in previous national and international studies. 15,21 The likelihood ratios (LR) in our study suggest that screening tools could be useful for clinicians.…”

Section: Discussionmentioning

confidence: 88%

Detecting Mood Disorder in Resource-Limited Primary Care Settings: Comparison of a self-administered screening tool to general practitioner assessment

et al. 2013

View full text Add to dashboard Cite

Objectives: Although efficacious treatments for mood disorders are available in primary care, under-diagnosis is associated with under-treatment and poorer outcomes. This study compares the accuracy of self-administered screening tests with routine general practitioner (GP) assessment for detection of current mood disorder. Methods: 197 consecutive patients attending primary care centres in Santiago, Chile enrolled in this cross-sectional study, filling out the Patients Health Questionnaire-9 (PHQ-9) for depression and the Mood Disorder Questionnaire (MDQ) for bipolar disorder, after routine GP assessment. Diagnostic accuracy of these self-administered tools was compared with GP assessment, with gold standard diagnosis established by a structured diagnostic interview with trained clinicians (SCID-I). Results: The sample was 75% female, with a mean age of 48.5 (SD 16.8); 37% had a current mood disorder (positive SCID-I result for depression or bipolar disorder). Sensitivity of the screening instruments (SI) was substantially higher than GP assessment (SI: 0. Conclusion: Self-administered screening tools are more accurate than GP assessment in detecting current mood disorder in low-income primary care. Such screening tests may improve detection of current mood disorder if implemented in primary care settings.

show abstract

Section: Discussionmentioning

confidence: 88%

Detecting Mood Disorder in Resource-Limited Primary Care Settings: Comparison of a self-administered screening tool to general practitioner assessment

et al. 2013

View full text Add to dashboard Cite

show abstract

“…The PHQ-9 has been validated in samples of patients with cancer and used in clinical trials with this population. 8,9 Patients were considered depression responders if they had MDS at baseline and displayed a Ն 50% reduction in PHQ-9 scores at 12 weeks, which is the standard criterion for response in depression treatment trials. 10 By using an intent-to-treat analysis, participants who met criteria for depression at baseline but did not survive to 12 weeks were considered nonresponders.…”

Section: Depressionmentioning

confidence: 99%

Depression and Survival in Metastatic Non–Small-Cell Lung Cancer: Effects of Early Palliative Care

Pirl

Greer

Traeger

et al. 2012

JCO

195

141

View full text Add to dashboard Cite

A B S T R A C T PurposeIn a randomized trial, early palliative care (EPC) in patients with metastatic non-small-cell lung cancer (NSCLC) was observed to improve survival. In a secondary analysis, we explored the hypothesis that the survival benefit resulted from improving depression. Patients and MethodsIn total, 151 patients with newly diagnosed metastatic NSCLC participated in a randomized trial of EPC integrated with standard oncology care versus standard oncology care alone. Depression was assessed at baseline and at 12 weeks with the Patient Health Questionnaire-9 (PHQ-9) and was scored diagnostically by using Diagnostic and Statistical Manual of Mental Disorders, 4th Edition, criteria for major depression syndrome (MDS). Depression response was considered Ն 50% reduction in PHQ-9 scores at 12 weeks. Survival differences were tested with log-rank and Cox proportional hazards models. ResultsAt baseline, 21 patients (14%) met MDS criteria. MDS significantly predicted worse survival (hazard ratio, 1.82; P ϭ .02). Patients assigned to EPC had greater improvements in PHQ-9 scores at 12 weeks (P Ͻ .001); among patients with MDS, those receiving EPC had greater rates of depression response at 12 weeks (P ϭ .04). However, improvement in PHQ-9 scores was not associated with improved survival, except in a sensitivity analysis in which patients who died before 12 weeks were modeled to have worse depression. The group randomly assigned to EPC remained independently associated with survival after adding improvement in PHQ-9 scores to the survival model. ConclusionDepression predicted worse survival in patients with newly diagnosed metastatic NSCLC. Although EPC was associated with greater improvement in depression at 12 weeks, the data do not support the hypothesis that treatment of depression mediated the observed survival benefit from EPC.

show abstract

“…This self-report instrument was developed to screen for major depressive disorder in primary care using the diagnostic criteria of the Diagnostic and Statistical Manual of Mental Disorders IV [16]. Investigators have since validated and used the measure in studies of patients with cancer [17,18]. In the current study, scores were evaluated as continuous values to assess symptom severity and categorically to identify probable cases of major depressive disorder (i.e., scores Ն10).…”

Section: Depressionmentioning

confidence: 99%

Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung Cancer

Pirl¹,

Traeger²,

Greer³

et al. 2011

The Oncologist

View full text Add to dashboard Cite

Introduction. Depression appears to be associated with worse survival from cancer, but underlying mechanisms for this association are unknown. In the present study, we explored the degree to which tumor genotype may be associated with depression in patients with non-small cell lung cancer (NSCLC). We examined differences in depression severity and rates of positive screens for major depressive disorder among newly diagnosed patients with stage IV NSCLC and known epidermal growth factor receptor (EGFR) genotype.Methods. Newly diagnosed patients (n ‫؍‬ 53) with metastatic NSCLC attending an initial thoracic oncology consultation completed self-report questionnaires regarding demographics, smoking behavior, and depression before meeting with their oncologist. Biopsy samples were subsequently genotyped, including screening for EGFR mutations. We conducted a retrospective chart review to obtain clinical data, in-

show abstract

Depression screening using the Patient Health Questionnaire‐9 administered on a touch screen computer

Cited by 125 publications

References 55 publications

Detecting Mood Disorder in Resource-Limited Primary Care Settings: Comparison of a self-administered screening tool to general practitioner assessment

Detecting Mood Disorder in Resource-Limited Primary Care Settings: Comparison of a self-administered screening tool to general practitioner assessment

Depression and Survival in Metastatic Non–Small-Cell Lung Cancer: Effects of Early Palliative Care

Tumor Epidermal Growth Factor Receptor Genotype and Depression in Stage IV Non-Small Cell Lung Cancer

Contact Info

Product

Resources

About